Skip to content

Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System

The AcChord Study: A Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04190602
Acronym
AcChord
Enrollment
500
Registered
2019-12-09
Start date
2020-02-09
Completion date
2027-12-31
Last updated
2020-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Valve Diseases, Mitral Regurgitation, Mitral Valve Disease, Mitral Valve Insufficiency, Mitral Valve Prolapse

Keywords

NeoChord, DS1000, Artificial Chordae, Mitral Valve Repair

Brief summary

The objective of this study is to evaluate the 5-year outcomes of participants with degenerative mitral valve disease treated with the NeoChord Artificial Chordae System, Model DS1000 in a post-market setting.

Detailed description

This study is an observational, single-arm, multicenter post-market registry. Both prospective and retrospective enrollment will be allowed. No additional invasive or burdensome examinations outside those routinely required for the standard mitral valve repair procedure will be requested.

Interventions

DEVICENeoChord Artificial Chordae Delivery System, Model DS1000

The intended use of the device is for the placement of artificial chordae when the natural chordae tendinae have become elongated or ruptured due to degenerative valve disease.

Sponsors

NeoChord
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Has Grade III Moderate or Grade IV Severe degenerative or mixed disease mitral valve regurgitation * Study procedure completed after 31 December 2016

Exclusion criteria

* Heavily calcified valves * Valvular retraction with severely reduced mobility * Active bacterial endocarditis * Complex mechanism of MR (leaflet perforation, etc.) * Significant tethering of leaflets * Inflammatory valve disease

Design outcomes

Primary

MeasureTime frameDescription
Level of Mitral Regurgitation Following the Index ProcedureCompletion of Index ProcedureLevel of mitral regurgitation per echocardiography

Secondary

MeasureTime frameDescription
Level of Mitral Regurgitation at 3-6 Months3-6 MonthsLevel of mitral regurgitation per echocardiography
Level of Mitral Regurgitation at 1 Year1 YearLevel of mitral regurgitation per echocardiography
Level of Mitral Regurgitation at 2 Years2 YearsLevel of mitral regurgitation per echocardiography
Level of Mitral Regurgitation at 4 Years4 YearsLevel of mitral regurgitation per echocardiography
Level of Mitral Regurgitation at 5 Years5 YearsLevel of mitral regurgitation per echocardiography
Level of Mitral Regurgitation at 3 Years3 YearsLevel of mitral regurgitation per echocardiography

Other

MeasureTime frame
Freedom from Mitral Valve Re-interventionFrom enrollment until date of mitral valve reintervention, up to 5 years
Freedom from All-Cause MortalityFrom enrollment until date of death, up to 5 years

Countries

Germany, Greece, Switzerland

Contacts

Primary ContactAlexandar Jonkers
ajonkers@neochord.com+31 610740977

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026